News
IART
28.41
-3.30%
-0.97
First Week of December 20th Options Trading For Integra LifeSciences Holdings (IART)
NASDAQ · 3d ago
Jefferies Sticks to Their Buy Rating for Integra Lifesciences (IART)
TipRanks · 3d ago
Weekly Report: what happened at IART last week (0415-0419)?
Weekly Report · 3d ago
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024
Integra LifeSciences Holdings Corporation has rescheduled the release of the Company's first quarter 2024 financial results to May 6, 2024. The company's management team will host a conference call at 8:30 a.m. EDT. Integra is a leading global medical technology company.
Barchart · 04/18 16:24
Weekly Report: what happened at IART last week (0408-0412)?
Weekly Report · 04/15 09:01
INTEGRA LIFESCIENCES HOLDINGS CORP <IART.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $37 FROM $41
Reuters · 04/15 08:25
ClearBridge Small Cap Growth Strategy Q2 2024 Portfolio Manager Commentary
Seeking Alpha · 04/09 15:00
Here's Why Investors Should Retain Integra (IART) Stock Now
NASDAQ · 04/09 12:41
Weekly Report: what happened at IART last week (0401-0405)?
Weekly Report · 04/08 09:01
Top buy-rated stocks and sell-rated stocks within Health Care - Citi
Citi Research strategists have lowered the health care sector to underweight. The company has struggled with “uninspiring” growth in equipment and services. Pharmaceuticals, biotechnology and life sciences are the top sell-rated stocks within the sector. The top buy-rated stock is Arcus Biosciences.
Seeking Alpha · 04/04 15:12
Integra LifeSciences Price Target Maintained With a $38.00/Share by Citigroup
Dow Jones · 04/03 15:41
Integra LifeSciences Raised to Neutral From Sell by Citigroup
Dow Jones · 04/03 15:41
Citigroup Upgrades Integra Lifesciences to Neutral, Maintains Price Target to $38
Benzinga · 04/03 15:30
*Integra LifeSciences Completes The Acquisition Of Acclarent, Inc. >IART
Dow Jones · 04/01 20:15
Press Release: Integra LifeSciences Completes the Acquisition of Acclarent, Inc.
Integra LifeSciences Completes the Acquisition of Acclarent, Inc. The company will release its first quarter 2024 financial results on April 25, 2024. The acquisition adds $1 billion to the total addressable market of Integra's brands. Integra is a pioneer in ear, nose and throat surgical interventions.
Dow Jones · 04/01 20:15
Weekly Report: what happened at IART last week (0325-0329)?
Weekly Report · 04/01 09:01
Why Is Integra (IART) Down 4% Since Last Earnings Report?
NASDAQ · 03/29 15:30
Weekly Report: what happened at IART last week (0318-0322)?
Weekly Report · 03/25 09:01
Positive Signs As Multiple Insiders Buy Integra LifeSciences Holdings Stock
Integra LifeSciences Holdings Corporation insiders bought US$300k worth of shares in the last year. The biggest single purchase by an insider was by Jan De Witte for US$38.50 per share. In the last 12 months Integra Lifescience Holdings insiders were net buyers of US$400k in shares. The company has a high level of insider ownership. Integra lifesciences holdings owns about 3.1% of the company. You should pay attention to the insider transactions in IntegraLifeSciENCE Holdings Corporation.
Simply Wall St · 03/21 13:56
Weekly Report: what happened at IART last week (0311-0315)?
Weekly Report · 03/18 09:01
More
Webull provides a variety of real-time IART stock news. You can receive the latest news about Integra Lifesciences Hldgs Cp through multiple platforms. This information may help you make smarter investment decisions.
About IART
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.